What is BPC 157? In one sentence: a synthetic pentadecapeptide based on a partial sequence of a protein found in gastric juice, studied mainly in rats for effects on healing tissue. It is not a hormone, not a steroid, and not an approved medicine anywhere.
The vendor we point lifters to
BPC-157 from Ascension Peptides
Independently assayed material, dispatched from the US. Both drop by half with the code below.
The Wolverine Stack is BPC-157 10 mg combined with TB-500 10 mg in one vial, so its per-mg figure spans both compounds. Quantity tiers take 3%, 5% or 10% off the list price; free shipping starts at $250.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 19, 2026.
The definition is easy. The useful part is the boundary around it, because this compound is discussed in circles where almost everything else being discussed is aimed at muscle growth, and it is not.
What is BPC 157 made from, and what does that tell you
Pentadecapeptide means a chain of fifteen amino acids. That is short. Insulin is larger, antibodies are vastly larger, and a chain of that length is small enough to be manufactured synthetically at scale and cheaply, which is one reason it circulates so widely in the research chemical market.
The original interest came from the gut. The sequence relates to a protein identified in gastric juice, and the earliest work examined protection of stomach and intestinal tissue in rats. Tendon, ligament and muscle findings came afterwards, and those are the ones that brought it to lifters.
Peptide is a category, not a mechanism. Compounds in that category range from insulin to signalling molecules with no relation to each other, so grouping them tells you as much about their effects as grouping drugs by tablet colour.
The boundaries, in both directions
The compact version, in both directions.
It is a synthetic peptide. It is the subject of a substantial rat and cell culture literature concerning tendon, ligament, muscle and gut healing, produced largely by a small number of research groups. It is currently in registered human trials aimed at injuries.
It is not approved by the FDA, the EMA or the MHRA, for any indication. It is not a growth hormone or a growth hormone releasing agent, whatever the vendor category implies. It is not anabolic: there is no established action on the myostatin pathway, no described effect on muscle protein synthesis, and no hypertrophy or performance data in humans. It is not a proven human treatment, because human trials exist and are registered while none has published efficacy results. And it is not a supplement in any regulated sense. It is sold as a research chemical.
Where the research actually sits
The efficacy record is animal and cell work. Rats with surgically transected Achilles tendons were reported to recover with better organised tissue and greater load tolerance than untreated animals. Rat models of knee ligament damage and crushed skeletal muscle reported improved structural and functional recovery. Rat studies on induced stomach and intestinal lesions, including damage from anti inflammatory drugs, reported protective effects.
At the cellular level, rat tendon fibroblasts in culture showed increased outgrowth and migration, along with changes in the signalling proteins governing how cells attach and move, and increased growth hormone receptor expression. That last detail is the origin of a persistent misreading: it describes connective tissue cells in a dish becoming more responsive to a local signal, not systemic hormone release and not an effect on skeletal muscle.
Vessel forming activity has been reported in endothelial cell culture and increased vascularity in healing rat tissue, which is the common thread underneath the healing results.
Two caveats belong with that summary. Much of this work comes from a small number of laboratories studying related models over many years, so internal consistency is high while independent replication is thinner than the citation count suggests. And rat healing is a generous model: the injuries are clean, created under anaesthesia, and the animal does not return to heavy training on partly repaired tissue a fortnight later.
Related reading on this compound: the dosing question, whether cycling applies here, the benefit claims graded by organism.
Questions worth clearing up before going further
Is it a steroid?
No. Steroids are lipid based hormones acting through nuclear receptors. This is a short amino acid chain with no described hormonal activity.
Is it legal?
Possession rules vary by country. It is not approved as a medicine anywhere, it is sold as a research chemical rather than for human use, and in sport it falls under the category covering non approved substances, which is prohibited at all times.
Does the body produce it naturally?
Not in this form. It is a synthetic sequence related to a protein found in gastric juice, not a naturally occurring molecule that has been isolated and bottled.
Are there any human results?
Registered trials exist and none has published efficacy results. NCT07437547 is a Phase 2 trial in 120 participants with acute hamstring strain, recruiting. NCT02637284 was a Phase 1 safety and pharmacokinetics study in 42 participants, status unknown.
What does the gut research have to do with training?
More than it appears. Rat work described protection against lesions caused by anti inflammatory drugs, and a lot of lifters run through those during a painful block. It remains rat evidence, so it establishes a research direction rather than a reason to combine anything.
Why is it discussed on a site about muscle?
Because the animal findings concern tendon, ligament and muscle repair, and injury is one of the main reasons lifters lose training time and therefore lean mass. The interest is repair, not growth.
What it keeps getting confused with
| Compound or category | Intended target | Evidence base | Relationship to muscle growth |
|---|---|---|---|
| BPC-157 | Tissue repair, gut and connective tissue | Rat and cell culture efficacy work, human trials registered without published results | None established |
| Growth hormone secretagogues | Pulsed growth hormone release | Human pharmacology exists, body composition claims contested | Indirect at best, heavily marketed |
| Myostatin pathway agents | Removing a brake on muscle mass | Investigated in humans for muscle wasting, none approved for healthy gain | Direct by design |
| Collagen supplementation with loaded rehabilitation | Connective tissue support | Human trials exist with mixed and modest findings | None claimed |
| Anabolic androgenic steroids | Muscle protein synthesis by hormone action | Extensive human data, well documented risks | Direct and substantial |
The point of that table is the second column. Only one row shares a target with this peptide, and it is the unglamorous one at the bottom of the connective tissue conversation rather than any of the growth entries. Anything promising both repair and mass from a single vial is selling two rows at once.
One more distinction gets lost in vendor copy. Repair and growth are separate biological problems with separate machinery. Growth is driven by mechanical loading, protein availability and hormonal signalling acting on muscle fibres. Repair after injury involves inflammation resolving, new blood vessels arriving, fibroblasts laying down collagen and that collagen slowly reorganising into tissue that can carry load. A compound acting on the second set of processes has no particular reason to touch the first, and nothing in the published record suggests this one does.
The regulatory position, without softening
No marketing authorisation exists from the FDA, the EMA or the MHRA. Products are sold labelled for research use, which means identity, purity, concentration and sterility are attested by the seller and verified by nobody. A certificate of analysis usually describes a batch, and often not the batch that arrived. That is not a technicality about paperwork, it is the reason a buyer cannot know what is in the container.
Why this audience found it at all
Lean mass past forty is mostly lost in steps, and the steps are injuries. A shoulder that ends overhead work, an Achilles that ends running, a back that turns a training year into a rehabilitation year. Muscle detrains fast and rebuilds slowly, and connective tissue is usually the tissue that failed, because tendon adapts and turns over more slowly than the muscle pulling on it.
A compound with a serious animal literature on tendon and ligament repair is therefore genuinely relevant to body composition, just not in the way it is usually sold. The relevance runs through training continuity across years, not through anything that would be visible in eight weeks. Whether the animal findings hold in humans is the open question, and the registered injury trials are the place it will be answered.
There is also a plain reason it stays popular despite all of this. It is cheap to synthesise, widely available, and the thing it promises, healing an injury that is standing between someone and their training, is the thing an injured lifter wants most. Demand of that kind does not wait for evidence, and a market with no verification requirement is happy to meet it.
What would move this from interesting to established
A published efficacy result from a controlled human trial, in a defined injury, with a comparison group and a pre specified outcome measure. Independent replication by groups unconnected to the original research programmes. Published pharmacokinetics, so exposure in humans is a measured quantity rather than an assumption scaled from rats. None of those exists yet. Until they do, the honest answer to what is BPC 157 remains the same: a well studied animal finding, awaiting a human test.